Lisanti Capital Growth LLC Buys 74,200 Shares of NeoGenomics, Inc. $NEO

Lisanti Capital Growth LLC purchased a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 74,200 shares of the medical research company’s stock, valued at approximately $1,362,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. First Light Asset Management LLC increased its stake in shares of NeoGenomics by 26.2% in the 2nd quarter. First Light Asset Management LLC now owns 12,279,523 shares of the medical research company’s stock worth $179,158,000 after acquiring an additional 2,549,545 shares in the last quarter. First Trust Advisors LP bought a new position in shares of NeoGenomics in the 1st quarter worth approximately $45,725,000. Dimensional Fund Advisors LP raised its position in NeoGenomics by 9.2% in the first quarter. Dimensional Fund Advisors LP now owns 2,674,335 shares of the medical research company’s stock worth $19,842,000 after acquiring an additional 225,588 shares during the period. American Capital Management Inc. bought a new stake in NeoGenomics during the second quarter valued at about $32,648,000. Finally, Bank of New York Mellon Corp bought a new position in shares of NeoGenomics during the 2nd quarter valued at approximately $10,744,000. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Price Performance

Shares of NeoGenomics stock opened at $16.83 on Thursday. The company has a quick ratio of 3.31, a current ratio of 3.53 and a debt-to-equity ratio of 0.47. The firm’s 50-day moving average price is $17.59 and its 200 day moving average price is $12.98. NeoGenomics, Inc. has a twelve month low of $7.07 and a twelve month high of $20.15.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Wednesday, October 28th. The medical research company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. NeoGenomics had a negative return on equity of 0.99% and a negative net margin of 4.10%. The firm had revenue of $209.25 million during the quarter, compared to the consensus estimate of $206.70 million. During the same period in the prior year, the company earned $0.03 EPS. The firm’s revenue was up 11.3% compared to the same quarter last year. On average, research analysts expect that NeoGenomics, Inc. will post -0.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NEO. Piper Sandler restated an “overweight” rating on shares of NeoGenomics in a research note on Wednesday, October 7th. Benchmark increased their price objective on shares of NeoGenomics from $11.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Jefferies Financial Group restated a “buy” rating and set a $21.00 price target on shares of NeoGenomics in a research note on Thursday, October 29th. Wall Street Zen upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating in a report on Sunday. Finally, Zacks Research downgraded NeoGenomics from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Eight research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.88.

NeoGenomics Profile

NeoGenomics is a cancer-focused diagnostics company that provides laboratory testing and related services to physicians, hospitals, pharmaceutical companies and other healthcare organizations. Its clinical testing helps support the diagnosis and treatment of cancer. The company offers a range of oncology tests, including molecular, cytogenetic, pathology and flow cytometry services. Its capabilities also include next-generation sequencing and liquid biopsy testing, which can help clinicians assess tumor characteristics and inform treatment decisions.